JP2025183279A5 - - Google Patents

Info

Publication number
JP2025183279A5
JP2025183279A5 JP2025146817A JP2025146817A JP2025183279A5 JP 2025183279 A5 JP2025183279 A5 JP 2025183279A5 JP 2025146817 A JP2025146817 A JP 2025146817A JP 2025146817 A JP2025146817 A JP 2025146817A JP 2025183279 A5 JP2025183279 A5 JP 2025183279A5
Authority
JP
Japan
Prior art keywords
seq
polypeptide sequence
bcma
polynucleotide
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025146817A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025183279A (ja
Filing date
Publication date
Priority claimed from PCT/CN2020/088836 external-priority patent/WO2020224606A1/zh
Application filed filed Critical
Publication of JP2025183279A publication Critical patent/JP2025183279A/ja
Publication of JP2025183279A5 publication Critical patent/JP2025183279A5/ja
Pending legal-status Critical Current

Links

JP2025146817A 2019-05-07 2025-09-04 Bcmaを標的とする操作された免疫細胞及びその使用 Pending JP2025183279A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201910376652 2019-05-07
CN201910376652.8 2019-05-07
PCT/CN2020/088836 WO2020224606A1 (zh) 2019-05-07 2020-05-06 靶向bcma的工程化免疫细胞及其用途
JP2021566227A JP7741732B2 (ja) 2019-05-07 2020-05-06 Bcmaを標的とする操作された免疫細胞及びその使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021566227A Division JP7741732B2 (ja) 2019-05-07 2020-05-06 Bcmaを標的とする操作された免疫細胞及びその使用

Publications (2)

Publication Number Publication Date
JP2025183279A JP2025183279A (ja) 2025-12-16
JP2025183279A5 true JP2025183279A5 (cg-RX-API-DMAC7.html) 2026-02-17

Family

ID=73051240

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021566227A Active JP7741732B2 (ja) 2019-05-07 2020-05-06 Bcmaを標的とする操作された免疫細胞及びその使用
JP2025146817A Pending JP2025183279A (ja) 2019-05-07 2025-09-04 Bcmaを標的とする操作された免疫細胞及びその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021566227A Active JP7741732B2 (ja) 2019-05-07 2020-05-06 Bcmaを標的とする操作された免疫細胞及びその使用

Country Status (21)

Country Link
US (3) US11840575B2 (cg-RX-API-DMAC7.html)
EP (2) EP4778585A2 (cg-RX-API-DMAC7.html)
JP (2) JP7741732B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220017914A (cg-RX-API-DMAC7.html)
CN (2) CN118184800A (cg-RX-API-DMAC7.html)
AU (1) AU2020270298A1 (cg-RX-API-DMAC7.html)
CA (1) CA3139346A1 (cg-RX-API-DMAC7.html)
DK (1) DK3967329T3 (cg-RX-API-DMAC7.html)
ES (1) ES3070005T3 (cg-RX-API-DMAC7.html)
FI (1) FI3967329T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20260598T1 (cg-RX-API-DMAC7.html)
IL (1) IL287873A (cg-RX-API-DMAC7.html)
LT (1) LT3967329T (cg-RX-API-DMAC7.html)
PL (1) PL3967329T3 (cg-RX-API-DMAC7.html)
PT (1) PT3967329T (cg-RX-API-DMAC7.html)
RS (1) RS68063B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202112382WA (cg-RX-API-DMAC7.html)
SI (1) SI3967329T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202600204T1 (cg-RX-API-DMAC7.html)
TW (1) TWI771677B (cg-RX-API-DMAC7.html)
WO (1) WO2020224606A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10086055B2 (en) * 2016-06-01 2018-10-02 Promab Biotechnologies, Inc. Adherent cancer cell line expressing a hematological tumor antigen
CN113226340A (zh) 2018-11-26 2021-08-06 恩卡尔塔公司 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
CN113784733B (zh) * 2019-05-07 2024-09-06 亘喜生物科技(上海)有限公司 靶向bcma的工程化免疫细胞及其用途
EP4778585A2 (en) * 2019-05-07 2026-07-22 Gracell Bioscience (Shanghai) Co., Ltd. Engineered immune cell targeting bcma and use thereof
US20220213434A1 (en) 2019-05-10 2022-07-07 The Regents Of The University Of California Modified pluripotent cells
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
CN114174325A (zh) * 2019-06-04 2022-03-11 恩卡尔塔公司 用于免疫疗法的工程化自然杀伤细胞和工程化t细胞的组合
CN115515983A (zh) * 2020-05-06 2022-12-23 亘喜生物科技(上海)有限公司 人源化cd19抗体及其应用
CN113024671B (zh) * 2020-12-31 2022-05-24 北京艺妙神州医药科技有限公司 一种抗bcma的抗体及其应用
CN112778427B (zh) * 2021-01-29 2022-03-15 武汉思安医疗技术有限公司 双特异性cs1-bcma car-t细胞及其应用
CN114317607B (zh) * 2021-12-31 2024-08-02 苏州桑尼赛尔生物医药有限公司 融合一代靶向cd7 car和二代靶向bcma的双靶点通用car-t细胞及制备方法
AU2023251864A1 (en) * 2022-04-13 2024-10-03 The Regents Of The University Of California Immune cell inhibition by immune checkpoint engagers
CN117143248A (zh) * 2022-05-24 2023-12-01 合源康华医药科技(北京)有限公司 靶向bcma-cd19的双特异性嵌合抗原受体及其应用
WO2023230581A1 (en) * 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
CN116023504B (zh) * 2022-06-07 2025-09-30 江苏蒙彼利生物科技有限公司 双特异性嵌合抗原受体(car)及其制备方法
EP4565262A2 (en) * 2022-08-05 2025-06-11 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma
CN116063556B (zh) * 2022-08-18 2023-06-16 再少年(北京)生物科技有限公司 Ips来源的car-nk细胞及其治疗癌症的用途
CN117305248A (zh) * 2022-09-09 2023-12-29 复星凯特生物科技有限公司 抗EGFR和cMet双特异性嵌合抗原受体及其应用
CN116814553A (zh) * 2023-03-30 2023-09-29 广州百吉生物制药有限公司 杀伤和存续能力增强型car-t细胞及其制备和应用
CN116444669B (zh) * 2023-04-04 2024-02-13 科弈(浙江)药业科技有限公司 靶向bcma car-t细胞人源化抗体
AU2024255572A1 (en) * 2023-04-11 2025-10-23 AbelZeta Inc. Bispecific chimeric antigen receptors targeting bcma and cd19
CN119350497A (zh) * 2023-07-24 2025-01-24 星尘生物科技(上海)有限公司 人源化抗cd19单链可变区片段及其用途
CN117126891A (zh) * 2023-08-30 2023-11-28 广东君厚生物医药有限公司 一种逆转录病毒表达载体及包括其的car-t细胞
CN121320261A (zh) * 2024-07-12 2026-01-13 南京驯鹿生物技术股份有限公司 靶向bcma和gprc5d的双特异性car-t细胞
CN120424217B (zh) * 2025-04-30 2026-03-06 立凌生物制药(苏州)有限公司 靶向b细胞抗原和t细胞抗原的多特异性抗体及其应用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
HUP9900956A2 (hu) 1998-04-09 2002-04-29 Aventis Pharma Deutschland Gmbh. Egyláncú, több antigéntkötőhely kialakítására képes molekulák, előállításuk és alkalmazásuk
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
CN101952312A (zh) 2007-07-31 2011-01-19 米迪缪尼有限公司 多特异性表位结合蛋白及其应用
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
CN102421801B (zh) 2009-03-10 2016-03-16 比奥根Ma公司 抗-bcma抗体
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
AU2013246443B2 (en) 2012-04-11 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting B-cell maturation antigen
US20130280220A1 (en) 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
IL305629A (en) * 2013-02-15 2023-11-01 Univ California Chimeric antigen receptor and methods of using it
WO2014151910A1 (en) 2013-03-15 2014-09-25 Amgen Inc. Heterodimeric bispecific antibodies
GB201317929D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
AU2014374055B2 (en) 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
CN107074957B (zh) * 2014-01-13 2021-05-07 希望之城公司 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法
ES2836743T3 (es) 2014-06-02 2021-06-28 Us Health Receptores de antígeno quiméricos que seleccionan como diana CD-19
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
US10829735B2 (en) 2015-07-21 2020-11-10 The Trustees Of The University Of Pennsylvania Methods for improving the efficacy and expansion of immune cells
EP3368903A1 (en) 2015-10-30 2018-09-05 GlaxoSmithKline Intellectual Property Development Limited Prognostic method
UA126657C2 (uk) 2016-02-03 2023-01-11 Емджен Рісерч (Мюнік) Ґмбг ОДНОЛАНЦЮГОВА КОНСТРУКЦІЯ АНТИТІЛА ДО BCMA І CD3<font face="Symbol">e</font>
MA44254A (fr) * 2016-02-17 2018-12-26 Seattle Genetics Inc Anticorps bcma et leur utilisation pour traiter le cancer et les troubles immunologiques
SG11201807489PA (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
EP3484455A2 (en) 2016-07-15 2019-05-22 Novartis AG Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
PL3896091T3 (pl) 2016-08-10 2024-04-29 Legend Biotech Ireland Limited Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania
CN109715199A (zh) 2016-09-14 2019-05-03 詹森生物科技公司 包含bcma特异性iii型纤连蛋白结构域的嵌合抗原受体及其用途
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
CA3042613A1 (en) 2016-11-11 2018-05-17 Autolus Limited Chimeric antigen receptor
CN118581046A (zh) 2016-11-22 2024-09-03 新加坡国立大学 用于t细胞恶性肿瘤免疫疗法的cd7表达阻滞剂和嵌合抗原受体
WO2018106732A1 (en) 2016-12-05 2018-06-14 Juno Therapeutics, Inc. Production of engineered cells for adoptive cell therapy
CN108395478A (zh) * 2017-02-04 2018-08-14 上海恒润达生生物科技有限公司 靶向bcma的嵌合抗原受体并对其双重修饰的方法及其用途
AU2018222741A1 (en) * 2017-02-17 2019-09-26 Unum Therapeutics Inc. Co-use of anti-BCMA antibody and antibody-coupled T celll receptor (ACTR) in cancer therapy and B cell disorders
AU2018269194B2 (en) 2017-05-15 2025-05-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bicistronic chimeric antigen receptors and their uses
CN118853581A (zh) 2017-06-21 2024-10-29 美商生物细胞基因治疗有限公司 嵌合抗原受体(CARs)、组合物及其使用方法
CN109593721B (zh) * 2017-09-30 2022-11-01 亘喜生物科技(上海)有限公司 具有自杀基因开关的靶向人间皮素的工程化免疫细胞
US11905528B2 (en) 2017-10-12 2024-02-20 Icell Gene Therapeutics Inc. Compound chimeric antigen receptor (cCAR) targeting multiple antigens, compositions and methods of use thereof
IL279063B2 (en) 2018-05-31 2026-05-01 Washington University St Louis Chimeric antigen receptor T cells for cancer treatment
BR112021002390A2 (pt) 2018-08-09 2021-05-11 Juno Therapeutics Inc processos para gerar células modificadas e suas composições
SI3844267T1 (sl) 2018-08-31 2025-10-30 Novartis Ag Postopki izdelave celic, ki izražajo receptorje himernega antigena
EP4578507A3 (en) 2018-11-01 2025-11-12 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions and methods for t cell engineering
CN109468283A (zh) 2018-11-30 2019-03-15 北京美康基免生物科技有限公司 一种基于cd19和bcma的双重嵌合抗原受体基因修饰的免疫细胞及其应用
CN109485734B (zh) 2018-12-30 2020-05-12 广州百暨基因科技有限公司 一种靶向bcma和cd19的双特异性嵌合抗原受体及其应用
WO2020210678A1 (en) 2019-04-12 2020-10-15 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
EP4778585A2 (en) * 2019-05-07 2026-07-22 Gracell Bioscience (Shanghai) Co., Ltd. Engineered immune cell targeting bcma and use thereof
CN113784733B (zh) * 2019-05-07 2024-09-06 亘喜生物科技(上海)有限公司 靶向bcma的工程化免疫细胞及其用途
WO2021108661A2 (en) 2019-11-26 2021-06-03 Novartis Ag Chimeric antigen receptors and uses thereof
CN115777017A (zh) * 2020-05-06 2023-03-10 亘喜生物科技(上海)有限公司 用于t细胞工程改造的组合物及方法
KR20260052102A (ko) * 2023-08-10 2026-04-17 그라셀 바이오테크놀로지스 (상하이) 컴퍼니, 리미티드 B 세포 자가면역 질환 치료에서 이중 표적 car-t 세포의 용도

Similar Documents

Publication Publication Date Title
JP2022531911A5 (cg-RX-API-DMAC7.html)
JP2023518134A5 (cg-RX-API-DMAC7.html)
JP2022061992A5 (cg-RX-API-DMAC7.html)
JP2022504802A5 (cg-RX-API-DMAC7.html)
JP2022542543A5 (cg-RX-API-DMAC7.html)
JP2021510521A5 (cg-RX-API-DMAC7.html)
JP2017529067A (ja) Cd3結合ドメイン
JP2010535012A5 (cg-RX-API-DMAC7.html)
JP2019532625A5 (cg-RX-API-DMAC7.html)
JP2024023228A5 (cg-RX-API-DMAC7.html)
JP2012525829A5 (cg-RX-API-DMAC7.html)
JP2017536341A5 (cg-RX-API-DMAC7.html)
JP2021521793A5 (cg-RX-API-DMAC7.html)
WO2023174396A1 (zh) 一种新型免疫调节剂的开发和应用
JP2010532764A5 (cg-RX-API-DMAC7.html)
EP3635014B1 (en) Hetero-dimeric multi-specific antibody format targeting at least cd3 and hsa
JP2011509245A5 (cg-RX-API-DMAC7.html)
JP2022542559A5 (cg-RX-API-DMAC7.html)
TWI922434B (zh) 一種融合蛋白及其用途
CA3116294A1 (en) Anti-l1cam antibody or antigen-binding fragment thereof and chimeric antigen receptor comprising same
JP2026016543A5 (cg-RX-API-DMAC7.html)
JP2022504826A5 (cg-RX-API-DMAC7.html)
JP2024541476A5 (cg-RX-API-DMAC7.html)
JP2024504162A5 (cg-RX-API-DMAC7.html)
CA3240254A1 (en) Anti-mesothelin polypeptides, proteins, and chimeric antigen receptors